Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results this Wednesday after market close. Here’s what to expect.
Inspire Medical Systems beat analysts’ revenue expectations by 1.9% last quarter, reporting revenues of $224.5 million, up 10.5% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is Inspire Medical Systems a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Inspire Medical Systems’s revenue to grow 11.1% year on year to $266.3 million, slowing from the 24.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.68 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Inspire Medical Systems has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2% on average.
Looking at Inspire Medical Systems’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Haemonetics’s revenues decreased 2.7% year on year, beating analysts’ expectations by 2.4%, and Envista reported revenues up 15%, topping estimates by 10.6%. Haemonetics traded down 10% following the results while Envista was up 17.8%.
Read our full analysis of Haemonetics’s results here and Envista’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Inspire Medical Systems is down 31.7% during the same time and is heading into earnings with an average analyst price target of $124.40 (compared to the current share price of $66.25).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.